Lilly has been chasing—and gaining on—its chief metabolic medicine rival Novo Nordisk and its counterpart GLP-1s Ozempic and ...

CorMedix projects Melinta products will generate between $125 million and $135 million in revenue this year. The company also ...

Garonit Pharmaceutical, an India-based API maker, plans to build a $46.1 million production plant in New York to produce ...

Vor Bio has handed Dallan Murray a swift return to the workforce. | Vor Bio has handed Dallan Murray a swift return to the ...

Aurobindo will shell out $250 million to acquire drugmaker Lannett, shoring up the Indian drugmaker’s footprint in the U.S.

Merck pulled off its $10 billion buyout of Verona Pharma last month with little of the wheeling and dealing that typically ...

The FDA has removed a pause in the use of Valneva’s chikungunya vaccine in older adults while tweaking the shot’s label with stricter language.

When Jazz Pharmaceuticals' incoming CEO Renee Gala takes the reins at the drugmaker next week, she'll have a brand-new launch ...

After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...

Werewolf Therapeutics is transforming its brand awareness and clinical trial recruitment efforts with a new campaign. | ...

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

When Bayer CEO Bill Anderson launched his Dynamic Shared Ownership (DSO) layoff plan—designed to save 2 billion euros ($2.3 billion) in 2026—he said it would be completed by the “end of 2025 at the | ...